NextCure NXTC 深 滬
已收盤 04-02 16:00:00 美东时间
10.72
+0.190
+1.80%
華盛通- 最 高10.72
- 今 開10.31
- 成交量 1.08万股
- 最 低 10.31
- 昨 收 10.53
- 總市值 3816.76万
- 52周最高 15.7399
- 市盈率 靜 --
- 換手率 0.30%
- 52周最低 3.4932
- 委 比 98.88%
- 總股本 356.04万
- 歷史最高 1308.00
- 量 比 0.34
- 振 幅 3.89%
- 歷史最低 2.688
- 每 手 1
- 風險率 3.37%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多NextCure and Simcere’s SIM0505 (CDH6 ADC) Abstract Accepted for ASCO 2026
NextCure and Simcere Zaiming announced the acceptance of an abstract for SIM0505, an investigational ADC targeting Cadherin-6 (CDH6) with a proprietary topoisomerase 1 inhibitor payload, at the 2026 ASCO meeting in Chicago. The Phase 1 study (NCT06792552) evaluates SIM0505 in advanced solid tumors, focusing on platinum-resistant ovarian cancer. NextCure holds global rights for SIM0505, excluding China, Hong Kong, Macau, and Taiwan, managed by Sim...
03-31 20:05
NextCure GAAP EPS of -$19.65
NextCure press release (NXTC): FY GAAP EPS of -$19.65. Cash, cash equivalents, and marketable securities as of December 31, 2025 were $41.8 million as compared to $68.6 million as of December 31, 2024...
03-06 15:47
NextCure Q4 EPS $(0.81) Beats $(2.42) Estimate
NextCure (NASDAQ:NXTC) reported quarterly losses of $(0.81) per share which beat the analyst consensus estimate of $(2.42) by 66.49 percent. This is a 83.54 percent increase over losses of $(4.92) per share from the same
03-06 05:14
NextCure Shares Update on Cancer Drug Trials, Cash Runway Extends Into 2027
NextCure, Inc. (NASDAQ:NXTC), a clinical-stage biopharmaceutical company committed to developing novel therapies to treat cancer, today provided updates for its two antibody drug conjugate (ADC) programs and reported a
01-23 20:05
BRIEF-Nextcure Provides Business Update
BRIEF-Nextcure Provides Business Update Jan 23 (Reuters) - NextCure Inc NXTC.O : NEXTCURE PROVIDES BUSINESS UPDATE NEXTCURE INC - SIM0505 PHASE 1 DATA UPDATE EXPECTED IN Q2 2026 NEXTCURE INC - EXPECTS FUNDS TO LAST INTO FIRST HALF OF 2027 Source text: ID:nGNX1GZ2wN Further company coverage: NXTC.O (
01-23 20:03
NextCure Provides Business Update
<p>NextCure, Inc. provided updates on its two antibody drug conjugate (ADC) programs. SIM0505 (CDH6 ADC) Phase 1 dose escalation data is expected in Q2 2026, with a focus on platinum-resistant ovarian cancer. The company is expanding clinical sites and drug supply for dose optimization. LNCB74 (B7-H4 ADC) has initiated higher dose cohorts in its Phase 1 study, prioritizing patients with high B7-H4 expression in breast and gynecological cancers, i...
01-23 12:00
NextCure Launches At-The-Market Stock Offering Program
NextCure ( ($NXTC) ) has shared an announcement. On December 19, 2025, NextCure...
2025-12-20 06:55
NextCure to Present at the Piper Sandler 37th Annual Healthcare Conference
NextCure, Inc. will participate in a fireside chat at the Piper Sandler 37th Annual Healthcare Conference on December 3, 2025. A live audio webcast will be available through the company’s website, with a replay archived for 30 days. NextCure focuses on developing innovative cancer therapies, including antibody-drug conjugates, targeting patients who do not respond to current treatments. The company emphasizes understanding biological pathways and...
2025-11-20 13:00
NextCure Raises $21.5M in Private Placement
NextCure ( ($NXTC) ) has issued an announcement. On November 12, 2025, NextCure...
2025-11-17 21:44
